LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Reddy's path into new drug discovery involved targeting specialty generics products in western markets to create a foundation for drug discovery. Development of specialty generics was an important step for the company's growing interest in the development of new chemical entities. The elements involved in creating a specialty generic, such as innovation in the laboratory, developing the compound, and sending the sales team to the market, are also stages in the development of a new specialty drug. Starting with specialty generics allowed the company to gain experience with those steps before moving on to creating brand-new drugs. Reddy's invested heavily in establishing R&D labs and is the only Indian company to have significant R&D being undertaken overseas. Dr. Reddy's Research Foundation was established in 1992 and in order to do research in the area of new drug discovery. At first, the foundation's drug research strategy revolved around searching for analogues. Focus has since changed to innovative R&D, hiring new scientists, especially Indian students studying abroad on doctoral and post-doctoral courses. In 2000, the Foundation set up an American laboratory in Atlanta, dedicated to discovery and design of novel therapeutics. The laboratory is called Reddy US Therapeutics Inc (RUSTI) and its main aim is the discovery of next-generation drugs using genomics and proteomics. Reddy's research thrust focused on large niche areas in western markets – anti-cancer, anti-diabetes, cardiovascular and anti-infection drugs.
For example, it has been shown that IPF patients who have a specific genotype in the mucin MUC5B gene polymorphism (see above) experience slower decline in FVC and significantly improved survival. Even if such data are interesting from a scientific point of view, the application in the clinical routine of a prognostic model based on specific genotypes is still not possible.
==== Down syndrome ==== Trisomy 21 or Down syndrome is the most common human chromosomal anomaly arising from abnormal chromosomal segregation in meiosis. The condition can occur during anaphase in meiosis(I) marking oocyte maturation before ovulation and/or during anaphase in meiosis (II) signifying fertilization. Metabolic impact during these stages is furthered by low vitamin B12. Methylation of homocysteine to methionine is affected, primarily by the (MTRR):c.66A>G polymorphism. Chronic homocysteine elevation increases s-adenosyl-L-homocysteine levels, consequently inhibiting methyltransferase activity and promoting DNA hypomethylation. Mothers homozygous for this mutation (GG phenotype) are at a greater risk of having a child with down syndrome compared to heterozygotes (GA phenotype). Geographically, Irish populations are more likely to be homogenous whilst north American populations are commonly heterogeneous, resulting in a greater incidence of the polymorphism in the former group. The homozygous mutant allele promotes DNA hypomethylation and meiotic non-disjunction, increasing the risk of down syndrome. This polymorphism correlates to a 2.5 fold risk increase independently and a 4 fold increase in risk when co-expressed with the 677C>T MTHFR mutation. Combination with the MTR2756A>G genetic polymorphism further elevates down syndrome risk.
== Structure == SUMO proteins are small; most are around 100 amino acids in length and 12 kDa in mass. The exact length and mass varies between SUMO family members and depends on which organism the protein comes from. Although SUMO has very little sequence identity with ubiquitin (less than 20%) at the amino acid level, it has a nearly identical structural fold. SUMO protein has a unique N-terminal extension of 10-25 amino acids which other ubiquitin-like proteins do not have. This N-terminal is found related to the formation of SUMO chains. The structure of human SUMO1 is depicted on the right. It shows SUMO1 as a globular protein with both ends of the amino acid chain (shown in red and blue) sticking out of the protein's centre. The spherical core consists of an alpha helix and a beta sheet. The diagrams shown are based on an NMR analysis of the protein in solution.
Sources: en.wikipedia.org
=== Drug design === A solvated ligand that binds the protein of interest is likely to exist as an equilibrium mixture of several conformers. Likewise the solvated protein also exists as several conformers in equilibrium. Formation of protein-ligand complex includes displacement of the solvent molecules that occupy the binding site of the ligand, to produce a solvated complex. Because this necessarily means that the interaction is entropically disfavored, highly favorable enthalpic contacts between the protein and the ligand must compensate for the entropic loss. The design of new ligands is usually based on the modification of known ligands for the target proteins. Proteases are enzymes that catalyze hydrolysis of a peptide bond. These proteins have evolved to recognize and bind the transition state of peptide hydrolysis reaction which is a tetrahedral intermediate. Therefore, the main protease inhibitors are tetrahedral intermediate mimics having an alcohol or a phosphate group. Examples are saquinavir, ritonavir, pepstatin, etc.
is a constant, and neither does it deal with the uniqueness of the Navier–Stokes equations with respect to any turbulence properties.) It is also worth pointing out that the components of the velocity vector are exactly those from the Pythagorean quadruple parametrization. Other choices of density and pressure are possible with the same velocity field:
Prime Minister Pedro Sánchez also said that they would not recognize a US intervention that violates international law after President Trump announced that the US would run Venezuela. Sweden: Prime Minister Ulf Kristersson stated that "Venezuela has been one of the world's most ruthless socialist dictatorships," adding that "the Venezuelan people have been freed from Maduro's dictatorship," whilst reiterating that "all states have a responsibility to respect and act in accordance with international law". Foreign Minister Maria Malmer Stenergard stated that "dictator Nicolás Maduro lacked democratic legitimacy. The Swedish government sheds no tears over the fact that he has lost power," but that "Venezuela's future must be decided by the Venezuelan people. Respecting the will of the Venezuelan people and achieving a negotiated, democratic, and peaceful solution is the only way for Venezuela to restore democracy and resolve the ongoing crisis." Switzerland: The Federal Department of Foreign Affairs stated that "Switzerland has called for de-escalation, restraint and respect for international law." The Swiss government later ordered to freeze potential assests by Maduro in the country. Turkey: Turkey said it was monitoring the situation in Venezuela, and urged restraint and called on all parties maintain order for the sake of regional and international security and safety. Ukraine: Foreign Minister Andrii Sybiha stated that "Ukraine has consistently defended the right of nations to live freely, free of dictatorship, oppression, and human rights violations.
Sources: en.wikipedia.org
The Mkhedrioni (Georgian: მხედრიონი, romanized: mkhedrioni) was a Georgian nationalist paramilitary organisation founded in 1989 by Jaba Ioseliani. It emerged during Georgia's transition to independence from the Soviet Union and played a major role in the Georgian Civil War and the War in Abkhazia. The Mkhedrioni was notorious for intimidation and criminal activities, including extortion, smuggling, robbery, and operating illegal roadblocks. It was banned by President Zviad Gamsakhurdia in 1991, regained influence after participating in the 1991–92 Georgian coup d'état that overthrew Gamsakhurdia, and was outlawed again in 1995 after the authorities accused Ioseliani and others of involvement in the attempted assassination of President Eduard Shevardnadze. After failing to secure registration to contest elections under its own name, it reconstituted itself as the Union of Patriots political party, which was also refused registration.
The Sanitary Board was established in 1883 in responsible of improving the sanitary conditions in the city as the result of Osbert Chadwick's report in 1881 advised. Under the 1887 Public Health Ordinance, the Board was composed of four official members and no more than six unofficial members, and that four official members should be appointed by the Governor (two of them being Chinese) and two elected by the ratepayers who were on the jury lists of the election year. Three elections were held in 1888, 1891 and 1894 respectively. The bubonic plague of 1894 raised the question of the composition and powers of the Board. The Government's decision of appointing a Medical Officer of Health to the Board in 1895 was against the will of the unofficial members. J. J. Francis, the three times elected member resigned, and other three unofficial members Ho Kai, William Hartigan and Robert Kennaway Leigh followed. The members of the Executive Council and the Chamber of Commerce were dissatisfied the sanitation and ineffectiveness of the Board. Prominent leaders including J. J. Keswick of the Chamber of Commerce, Paul Chater and E. R. Belilios were in favour of an official majority while the officers directly responsible to the Governor. Contrast to the abolition of the Board, Ho Kai represented another opinion of maintaining the unofficial majority and larger power of the unofficial members.
In physics, a vapor (American English) or vapour (Commonwealth English; see spelling differences) is a substance in the gas phase at a temperature lower than its critical temperature, which means that the vapor can be condensed to a liquid by increasing the pressure on it without reducing the temperature of the vapor. A vapor is different from an aerosol. An aerosol is a suspension of tiny particles of liquid, solid, or both within a gas. For example, water has a critical temperature of 647 K (374 °C; 705 °F), which is the highest temperature at which liquid water can exist at any pressure. In the atmosphere at ordinary temperatures gaseous water (known as water vapor) will condense into a liquid if its partial pressure is increased sufficiently. A vapor may coexist with a liquid (or a solid). When this is true, the two phases will be in equilibrium, and the gas-partial pressure will be equal to the equilibrium vapor pressure of the liquid (or solid).
Oparin was born in Uglich in 1894 into a merchant family. He and his parents soon moved to Kokayevo, a nearby village. Oparin had an older brother, Dmitry, who became an economist. Oparin graduated from the Moscow State University in 1917 and became a professor of biochemistry there in 1927. Many of his early papers were about plant enzymes and their role in metabolism. His first experimental studies were devoted to the chemistry of respiration. In them, he showed that chlorogenic acid is an essential component of redox reactions in the cell. In 1924 he put forward a hypothesis suggesting that life on Earth developed through a gradual chemical evolution of carbon-based molecules in the Earth's primordial soup. In 1935, along with academician Aleksei Bach, he founded the Biochemistry Institute of the Soviet Academy of Sciences. In 1939, Oparin became a Corresponding Member of the Academy, and, in 1946, a full member. In 1937, he organized the Department of Technical Biochemistry at the Moscow Technological Institute of Food Industry. In 1940s and 1950s, Oparin supported the theories of Trofim Lysenko and Olga Lepeshinskaya, who made claims about "the origin of cells from noncellular matter". "Taking the party line" helped advance his career. However, according to cytologist Vladimir Alexandrov:
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.